Acadia Completes Enrollment in ACP-104 Trial

Acadia has enrolled all patients in its Phase IIb trial of ACP-104 in schizophrenic patients.

The 248-patient, multicenter, double-blind, placebo-controlled trial will evaluate the safety and efficacy of the drug in patients experiencing an acute psychotic episode.

Patients were enrolled in one of three study arms, with patients receiving either 100 or 200 mg twice daily or placebo for six weeks. The primary endpoint of the trial is antipsychotic efficacy as measured by the Positive and Negative Syndrome Scale.

Acadia said it expects to report top-line results from this trial during the second quarter of 2008.